FENC

Fennec Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

8.410

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

8.410

Open

8.410

VWAP

8.41

Vol

2.36K

Mkt Cap

232.27M

Low

8.410

Amount

19.84K

EV/EBITDA(TTM)

Total Shares

27.32M

227.80M

EV/OCF(TTM)

P/S(TTM)

7.43

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

15.47M

+95.18%

13.45M

+92.85%

9.56M

+31.67%

Estimates Revision

The market is revising Upward the revenue expectations for Fennec Pharmaceuticals Inc. (FENC) for FY2025, with the revenue forecasts being adjusted by 11.37% over the past three months. During the same period, the stock price has changed by 37.64%.

Revenue Estimates for FY2025

Revise Upward

+11.37%

In Past 3 Month

Stock Price

Go Up

+37.64%

In Past 3 Month

3 Analyst Rating

62.54% Upside

Wall Street analysts forecast FENC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FENC is 13.67 USD with a low forecast of 13.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

62.54% Upside

Current: 8.410

Low

13.00

Averages

13.67

High

15.00

62.54% Upside

Current: 8.410

Low

13.00

Averages

13.67

High

15.00

Craig-Hallum

Buy

maintain

$12 -> $13

2025-05-14

Reason

Craig-Hallum

Price Target

$12 -> $13

2025-05-14

maintain

Buy

Reason

Craig-Hallum raised the firm's price target on Fennec to $13 from $12 and keeps a Buy rating on the shares following the company's Q1 earnings beat. The results for Q1 are near the breakeven amount for revenue, the firm notes. Craig-Hallum says that continued wins at potential major accounts, along with improved adherence to treatment from investments in the commercial team, could start to inflect the AYA channel.

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$13

2025-03-11

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$13

2025-03-11

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$13

2024-12-17

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$13

2024-12-17

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$15 → $13

2024-08-22

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$15 → $13

2024-08-22

Maintains

Strong Buy

Reason

Craig-Hallum

Chase Knickerbocker

Strong Buy

Maintains

$17 → $15

2024-08-14

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$17 → $15

2024-08-14

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Fennec Pharmaceuticals Inc (FENC.O) is 26.08, compared to its 5-year average forward P/E of 2.29. For a more detailed relative valuation and DCF analysis to assess Fennec Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

2.29

Current PE

26.08

Overvalued PE

52.10

Undervalued PE

-47.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

3.30

Current EV/EBITDA

11.91

Overvalued EV/EBITDA

15.93

Undervalued EV/EBITDA

-9.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

19.54

Current PS

4.45

Overvalued PS

58.04

Undervalued PS

-18.96